# Hangzhou Tangji Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-tangji-medical-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.tangjimed.com
- Total disclosed funding: $22M
- Latest round: Series C (Feb 5, 2025)
- Investors on record: 14

## About

Based in Hangzhou, China and established in 2016, Hangzhou Tangji Medical Technology Co.,Ltd is a medical device for metabolic diseases developer. In March 2017, a sample of its Gastric Bypass Stent System was produced. In December 2018, the scientific and clinical research of Gastric Bypass Stent System was initiated. Its development of gastric bypass stent system was under the procedure of medical device inspection by National Medical Products Administration (NMPA) in August of 2020. In January 2021, the registered clinical trial of the Gastric Bypass Stent System was initiated. In February 2025, the firm raised CNY 100 million in series C funding.

The company focuses on the treatment of metabolic diseases such as diabetes, obesity, and non-alcoholic fatty liver disease. The company's products can be categorized into gastric bypass stent systems and endoscopic interventional therapy products. Gastric bypass stent system can be used to control metabolic diseases, which contains advantages of being less invasive, and not damaging the human body structure. The company has dozens of R & D personnel, including one doctor and six masters. The company gained more than 20 patents all over the world.


The company’s revenue is generated by providing gastrointestinal interventional therapy and related medical devices.

The company will use the series C funding to accelerate the pace of promotion in China and international markets, advance the registration of clinical trials, build production lines, and expand production scale.

## Funding rounds

- Series C, Feb 5, 2025, $14M — Everest VC, Xin'an Capital
- Series B, Aug 31, 2023 — Chengdu Venture Capital, Geuniom Group
- Series B, Mar 23, 2023 — NNFE
- Series B, Jun 16, 2022 — Topping Capital, Guolian Group
- Series C, May 11, 2021, $8.5M — Everest VC, Baidu Ventures, Dingxin Capital
- Series B, Jul 30, 2019 — Sigma Square Capital
- Series A, Jun 15, 2018 — Dingxin Capital, Zheda Youchuang Capital
- Series A, Mar 22, 2018 — Virtus Inspire Ventures, Proxima Ventures, Haizhao Capital

## Investors

- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series A
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series A
- Haizhao Capital — Series A
- Dingxin Capital — Series A, Series C
- Zheda Youchuang Capital (https://capitalatlas.ai/funds/zheda-youchuang-capital) — Series A
- Sigma Square Capital (https://capitalatlas.ai/funds/sigma-square-capital) — Series B
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series C
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series C
- Topping Capital (https://capitalatlas.ai/funds/topping-capital) — Series B
- Guolian Group (https://capitalatlas.ai/funds/guolian-group) — Series B
- NNFE (https://capitalatlas.ai/funds/nnfe) — Series B
- Chengdu Venture Capital (https://capitalatlas.ai/funds/chengdu-venture-capital) — Series B
- Geuniom Group — Series B
- Xin'an Capital (https://capitalatlas.ai/funds/xin-an-capital) — Series C